AlphaMadera's AlphaVal page computes Bausch Health Companies Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag BHC as undervalued, fairly valued, or overvalued.

What is Bausch Health Companies Inc.'s fair value?

Fair value for BHC is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value BHC?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from BHC's most recent reported fundamentals.

BHC - Bausch Health Companies Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $8.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: BHC revenue per share ($28) is 6x the stock price ($4.76). Financials likely reported in a foreign currency.